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Abstract
Background: Microsatellite instability (MSI) occurs in 15% of colorectal cancers (CRC). The genetic targets for mutation 
in the MSI phenotype include somatic mutations in the transforming growth factor beta receptor typeII (TGFbetaRII), BAX, 
hMSH3 and hMSH6. It is not clear how mutations of these genes mediate tumor progression in the MSI pathway, and 
the temporal sequence of these mutations remains uncertain. In this study, early stage CRCs were examined for 
frameshift mutations in these target genes, and compared with late stage tumors and CRC cell lines.
Methods: We investigated 6 CRC cell lines and 71 sporadic CRCs, including 61 early stage cancers and 10 late stage 
cancers. Mutations of repetitive mononucleotide tracts in the coding regions of TGFbetaRII, BAX, hMSH3, hMSH6, IGFIIR 
and Fas antigen were identified by direct sequencing.
Results: Thirteen (18.3%) of 71 CRC, including 9/61 (14.7%) early stage cancers and 4/10 (40%) late stage cancers, were 
identified as MSI and analyzed for frameshift mutations. No mutation in the target genes was observed in any of the 9 
early stage MSI CRCs. In contrast, frameshift mutations of TGFbetaRII, BAX, hMSH3 and hMSH6 were present in 3/4 late 
stage MSI tumors. There is a statistical association (p = 0.014) between mutation in any one gene and tumor stage.
Conclusions: TGFbetaRII, BAX, hMSH3 and hMSH6 mutations are relatively late events in the genesis of MSI CRCs. The 
frameshift mutations in these target genes might mediate progression from early to late stage cancer, rather than 
mediating the adenoma to carcinoma transition.
Background
Microsatellite instability (MSI) is present in 15% of col-
orectal carcinomas (CRCs)[1]. Inactivation of the DNA
mismatch repair (MMR) system leads to widespread
somatic mutations at microsatellite loci. MSI tumors have
been found to display microsatellite alterations not only
in introns but also in coding exons. Genetic targets of this
type of genomic instability include the transforming
growth factor β receptor type II (TGFβRII), insulin-like
growth factor II receptor (IGFIIR), BAX, Fas antigen,
hMSH3 and hMSH6, all of which contain mononucle-
otide repeats in coding sequences [2,3]. Although it has
been reported that MSI in introns is an early event in spo-
radic colorectal carcinogenesis [4,5], it is not known how
mutations of these target genes are involved in tumor
progression along the MSI pathway [2]. This study exam-
ined whether the frequency frameshift mutations in
mononucleotide repeat regions within exons increases
with stage in microsatellite unstable colorectal cancer.
"Early stage cancer" was defined as intramucosal carci-
noma, either carcinoma in situ or invasive cancer con-
fined within the submucosa. For this study, "late stage
cancer" was defined as any cancer invading the muscu-
laris propria or serosa. Molecular events in early CRCs
have not been well elucidated because of the limited
availability of these cancers for detailed studies [5]. In this
study, early stage MSI CRCs were examined for somatic
frameshift mutations in the TGFβRII, IGFIIR and BAX,
hMSH3 and hMSH6 genes, and compared with CRCS at
more advanced stages and CRC cell lines.
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Cell lines
Six CRC cell lines: HCT116, LoVo, SW480, LS174t, DLD1
and HT29, were obtained from the American Type Cul-
ture Collection (Rockville, MD), and maintained in tissue
culture containing 10% fetal calf serum (GIBCO) at 37°C.
LoVo, DLD1, SW480 and LS174t were derived from late
stage colorectal cancer: LoVo [6] and DLD1 [7] were
derived from Dukes' C tumor, and SW480 [8] and LS174t
[9] were from Dukes' B tumor. Tumor stage of HCT116
[10] and HT29 [11] were not informative.
Tumor tissues
Seventy-one CRCs, including 61 early stage cancers and
10 late stage cancers, were collected for analysis. The his-
topathological diagnosis was determined according to the
classification by the World Health Organization (WHO)
[12] or by the General Rules of the Japanese Research
Society for Cancer of Colon and Rectum [13]. Lymph
node status was not taken into account. The tumor tis-
sues were microdissected from formalin-fixed, paraffin-
embedded tissues sections as previously described [14].
Normal tissues were obtained from histologically normal
mucosa or normal lymph nodes of the same patients.
This study was approved by the Osaka City University
ethics committee. Informed consent was obtained from
all patients.
DNA extraction
Genomic DNA from the cell lines was extracted with
phenol-chloroform. Genomic DNA from tumor tissues
was isolated using Proteinase K (Sigma, St. Louis, MO) at
a final concentration of 100 μg/ml and were incubated for
5 h at 55°C [14].
Identification of MSI
DNA was amplified by polymerase chain reaction (PCR)
using 32 P-end-labeled primers at microsatellite loci
linked to the hMSH2 locus on 2p16 (CA-5 and D2S123),
the hMLH1 locus on 3p23-21.3 (D3S1611 and D3S1561),
the APC/MCC locus on 5q21 (D5S107 and D5S346), the
p53 locus on 17p13 (D17S513 and p53 intron 1), and the
DCC/SMAD4 locus on 18q21.3 (D18S35A and 18qDCC-
TA) [14]. We utilized stringent criteria for the determina-
tion of MSI from a National Cancer Institute workshop
[15]. MSI-high (referred to as MSI) was defined by a
novel band shift or allele at >20% of the microsatellite loci
tested when compared to non-neoplastic tissue from the
same patient. Our assay for MSI was based on PCR
amplification of a panel of 10 microsatellite primer pairs
linked to tumor suppressor genes. In addition, poly (T)27
mononucleotide repeats in the noncoding region of β-
catenin exon 16 was performed using the following
primer sets: 5'-GGTACTGACTTTGCTTGCTT-3' and
5'-ACTTAACACTACGAGAGACT-3'. In each case, one
of the primer pairs was end-labeled with [γ-32P]ATP and
subjected to PCR. The resulting PCR products were ana-
lyzed for MSI by electrophoresis in 8% polyacrylamide gel
containing 7.5 M urea and 0.5× TBE.
Frameshift mutation analysis
Mutations of repetitive mononucleotide tracts in the cod-
ing regions of TGFβRII, IGFIIR, BAX, hMSH3, hMSH6
and Fas antigen were identified using the following
primer sets; 5'-CTTTATTCTGGAAGATGCTGC-3' and
5'-GAAGAAAGTCTCACCAGGC-3' for the poly(A)10
tract of TGFβRII, 5'-GCAGGTCTCCTGACTCAGAA-3'
and 5'-GAAGAAGATGGCTGTGGAGC-3' for the
poly(G)8 tract of IGFIIR, 5'-ATCCAGGATCGAGCAG-
GGCG-3' and 5'-ACTCGCTCAGCTTCTTGGTG-3' for
the poly(G)8 tract of BAX, 5'-AGCTGGATGATGCTG-
TAAAT-3' and 5'-TTCCTCACCTGCAAAGTACT-3' for
the poly(A)8 tract of hMSH3, 5'-CGCCCAGTAATTCT-
GTTG-3' and 5'-CATTTTCCTGCTCCTCTTC-3' for
the poly(C)8 tract of hMSH6, and 5'-ACCCGGACCCA-
GAATACCAA-3' and 5'-GCAAGGGTCACAGTGT-
TCAC-3' for the poly(T)7 tract of Fas antigen. To confirm
mutations observed as band shifts, DNA was excised
from the gel, purified with the Microspin columns (Phar-
macia Biotec, Inc., Uppsala, Sweden), and reamplified
with the same primer. The amplified products were
sequenced by the dideoxychain termination method, with
the AmpliCycle sequencing kit (Perkin-Elmer, Branch-
burg, NJ).
Results
Frameshift mutations in CRC cell lines
It has been reported that HCT116, LoVo, LS174t and
DLD1 have the MSI phenotype, whereas SW480 and
HT29 do not [16]. In this study, frameshift mutations in
the (A)10 tract of TGFβRII were found in all 4 MMR-defi-
cient cell lines: HCT116, LoVo, LS174t and DLD1. All cell
lines have only mutant alleles of TGFβRII, either (A)9 or
(A)8. Microsatellite alterations in the (G)8 tract of BAX
were present in HCT116, LoVo and LS174t. LoVo and
LS174t cells had only (G)9 and (G)7 mutant BAX alleles;
HCT116 had one (G)7 mutant allele and one (G)8wild-
type allele. Deletions in the (A)8 tract of the coding
sequence of hMSH3 were present in HCT116. Insertion
and deletion mutations in the (C)8 tract of hMSH6 were
detected in HCT116 and LS174t, respectively. In con-
trast, the MMR-proficient cell lines SW480 and HT29
demonstrated microsatellite stability, and did not have
mutations in TGFβRII, BAX, hMSH3 or hMSH6. No
alterations in the (G)8 tract of IGFIIR or the (T)7 tract of
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(Figure 1).
Frequencies of frameshift mutations in early and late stage 
sporadic MSI CRCs
Thirteen of 71(18.3%) sporadic CRCs, including 9/61
(14.7%) early stage CRCs and 4/10 (40%) late stage can-
cers were identified as MSI tumors (Table 1), and these
tumors were analyzed for frameshift mutations. Muta-
tions in the noncoding region of β-catenin, which con-
tains a (T)27 sequence, were present in 7/9 MSI early stage
CRCs (patients 1-9) and 3/4 MSI-H late stage CRCs
(patients 10-13) (Figure 2A). No frameshift mutations in
the target genes were present in any MSI early stage
CRCs. In contrast, frameshift mutations of TGFβRII,
BAX, hMSH3 and hMSH6 were present in 3/4 late stage
CRCs (Table 1). A significant difference (p = 0.014) was
found in the frequency of frameshift mutations between
early stage and. late stage (Table 2). TGFβRII and BAX
mutations were found in the late stage tumors of patients
11 and 10, respectively (Figure 2B). hMSH3 mutations
were present in patients 11 and 12, and an hMSH6 muta-
tion was found in patient 12. Each mutation was found to
be a 1 bp deletion in the polynucleotide tract (Figure 3).
No frameshift mutations in IGFIIR or Fas antigen were
found in any CRC.
Discussion
Although CRCs with the MSI phenotype evolve because
of loss of DNA MMR activity, there is little consensus on
the sequence and timing of target gene inactivation in the
evolution of tumors that occur through this pathway. It
has been reported that the appearance of MSI, at least at
noncoding microsatellites, is an early event in Lynch syn-
drome CRCs [4,17], and that frameshift alterations in the
functionally critical target genes may occur at an early
stage in these tumors [18-20]. TGFβRII frameshift muta-
tions are present in 80-90% of MSI CRCs, and it has been
reported that these occur at the adenoma-carcinoma
transition in MSI adenomas [21,22]. The precise timing
of the onset of MSI, and the occurrence of mutations at
other genetic targets, have not been confidently deter-
mined.
In this study, we examined the timing of frameshift
mutations of TGFβRII, IGFIIR, BAX, hMSH3, hMSH6
and Fas antigen in 9 early stage and 4 late stage MSI
CRCs. Interestingly, no mutations were identified in any
early stage MSI-H CRC at TGFβRII, BAX, hMSH3 or
hMSH6 , but these were relatively frequent events in late
stage MSI CRCs, and in the MSI CRC cell lines. There is a
statistical association between mutation in any one gene
and tumor stage. The frequency of frameshift mutations
in mononucleotide repeat regions within exons might
increase with stage in microsatellite unstable colorectal
cancer. Our findings suggest that TGFβRII, BAX, hMSH3
and hMSH6 frameshift mutations are relatively later stage
events in tumor progression for sporadic CRC with MSI.
It has been reported that TGFβRII mutations are infre-
quent in the early stages of sporadic gastric cancers with
MSI [23], but these occur more frequently in gastric
tumors that are larger [24]. It has been reported that the
loss of TGFβRII in intestinal epithelial cells promotes the
invasion and malignant transformation of tumors initi-
ated by APC mutations [25]. However, few studies have
clarified how mutations of the target genes we have stud-
ied mediate tumor development in the MSI pathway.
These findings suggested that the mutations of TGFβRII,
BAX, hMSH3, and hMSH6 might play an important role
in cancer progression from early to late stage tumors,
rather than early in carcinogenesis. However, there still
may be additional, currently unappreciated genes or
DNA sequences involved in the process [18,26-28]. Inter-
estingly, no microsatellite mutations in IGFIIR and Fas
Figure 1 Frameshift mutations in CRC cell lines. Lane a: products 
from normal control DNA. The products of MSI cell lines are shown in 
Lanes b (HCT116), c (LoVo), e (LS174-T) and f (DLD1). Products of non-
MSI cell lines are shown in Lanes d (SW480) and g (HT29). The genes are 
























































Table 1: Frameshift mutations in MSI CRCs
Patient number Stage Depth of invasiona Tumor size Locationb MSI Mutations in mononucleotide repeat tracts
(mm) TGFβRII BAX hMSH3 hMSH6 IGFIIR Fas antigen
1 Early m 4 A 2/6 - c - NId - - -
2 Early m 4 A 2/8 - - NI - - -
3 Early m 3 S 3/8 - - - - - -
4 Early sm 8 R 3/8 - - - - - -
5 Early sm 14 A 2/5 - - NI - - -
6 Early sm 8 T 3/8 - - - - - -
7 Early sm 4 D 3/10 - - - - - -
8 Early sm 12 NI 2/8 - - NI - - -
9 Early sm 13 R 2/9 - - - - - -
10 Late mp 9 R 2/8 - De - - - -
11 Late mp 20 S 3/9 De e - De - - -
12 Late mp 65 A 4/10 - - De De - -
13 Late mp 24 S 2/9 - - - - - -
am, carcinoma tissues were restricted to the mucosa; sm, the deepest carcinoma invasion was in the submucosa; mp, the deepest carcinoma penetration reached the muscularis propria.
bA, ascending colon; T, transverse colon; D descending colon; S, sigmoid colon; R, rectum.
c -, wild type.
d NI, not informative.
e De, deletion.
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also been reported that no mutations in the IGFIIR genes
were found in 27 MSI-H gastric tumors [29]. These find-
ings suggest that mononucleotide repeat of IGFIIR and
Fas antigen might be unimportant as target genes in
MMR-deficient CRCs. A limitation of our study is the
small number of tumor samples, while a significant dif-
ference between the early stage cancer and late stage can-
cers was recognized. Large numbers of patients with MSI
cancer might be necessary in the future to conclude the
correlation between tumor stage and frameshift muta-
tions in target gene.
Conclusions
Our data confirm that MSI can be found very early in the
evolution of a colorectal tumor with MSI, we propose
that not all sequence alterations are equivalent, and that
mutations in the coding microsatellites of TGFβRII and
BAX mediate progression from early to late stage CRC
with MSI. These finding raise interesting possibilities for
diagnosis as well as treatment.
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Figure 2 Frameshift mutations in CRCs with MSI. The genes are in-
dicated at the left. Arrowheads indicate 1 bp deletion mutations in tu-
mors. T and N refer to DNA from tumors and corresponding normal 
tissues, respectively.
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Table 2: Correlation between tumor stage and frameshift 
mutations.
Frameshift mutation
Tumor stage positive negative p value
Early 0 9
Late 3 1 0.014
Significance level of difference was determined using Fisher's 
exact test.
Figure 3 Sequence analysis of frameshift mutations in late stage 
CRCs. Single one bp deletions in the mononucleotide repeats were 
found in each case.
Normal (A)10 Tumor (A)9
A C G T A C G T
Patient 11
TGF-RII
Normal (A)8 Tumor (A)7
A C G T A C G T
Patient 12
hMSH3
Tumor (G)7 Normal (G)8
A C G T A C G T
Patient 10
BAX
Normal (C)8 Tumor (C)7
A C G T A C G T
Patient 12
hMSH6
Yashiro et al. BMC Cancer 2010, 10:303
http://www.biomedcentral.com/1471-2407/10/303
Page 6 of 6Acknowledgements
We thank Christina Chang, PhD for technical assistance and critical review of 
the manuscript.
Author Details
1Department of Surgical Oncology, Osaka City University Graduate School of 
Medicine, Osaka, Japan, 2Oncology Institute of Geriatrics and Medical Science, 
Osaka City University Graduate School of Medicine, Osaka, Japan and 3Division 
of Gastroenterology, Baylor University Medical Center, Dallas, Texas, USA
References
1. Boland CR: The molecular biology of gastrointestinal cancer: 
implications for diagnosis and therapy.  Gastrointestinal endoscopy 
clinics of North America 2008, 18(3):401-413. vii
2. Arnold CN, Goel A, Blum HE, Boland CR: Molecular pathogenesis of 
colorectal cancer: implications for molecular diagnosis.  Cancer 2005, 
104(10):2035-2047.
3. Yamamoto H, Gil J, Schwartz S Jr, Perucho M: Frameshift mutations in 
Fas, Apaf-1, and Bcl-10 in gastro-intestinal cancer of the microsatellite 
mutator phenotype.  Cell death and differentiation 2000, 7(2):238-239.
4. Pedroni M, Sala E, Scarselli A, Borghi F, Menigatti M, Benatti P, Percesepe A, 
Rossi G, Foroni M, Losi L, et al.: Microsatellite instability and mismatch-
repair protein expression in hereditary and sporadic colorectal 
carcinogenesis.  Cancer research 2001, 61(3):896-899.
5. Kambara T, Matsubara N, Nakagawa H, Notohara K, Nagasaka T, Yoshino T, 
Isozaki H, Sharp GB, Shimizu K, Jass J, et al.: High frequency of low-level 
microsatellite instability in early colorectal cancer.  Cancer research 
2001, 61(21):7743-7746.
6. Drewinko B, Romsdahl MM, Yang LY, Ahearn MJ, Trujillo JM: 
Establishment of a human carcinoembryonic antigen-producing colon 
adenocarcinoma cell line.  Cancer research 1976, 36(2 Pt 1):467-475.
7. Dexter DL, Barbosa JA, Calabresi P: N,N-dimethylformamide-induced 
alteration of cell culture characteristics and loss of tumorigenicity in 
cultured human colon carcinoma cells.  Cancer research 1979, 
39(3):1020-1025.
8. Leibovitz A, Stinson JC, McCombs WB, McCoy CE, Mazur KC, Mabry ND: 
Classification of human colorectal adenocarcinoma cell lines.  Cancer 
research 1976, 36(12):4562-4569.
9. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD: Human 
colonic adenocarcinoma cells. I. Establishment and description of a 
new line.  In vitro 1976, 12(3):180-191.
10. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE: 
Heterogeneity of malignant cells from a human colonic carcinoma.  
Cancer research 1981, 41(5):1751-1756.
11. Chen TR, Drabkowski D, Hay RJ, Macy M, Peterson W Jr: WiDr is a 
derivative of another colon adenocarcinoma cell line, HT-29.  Cancer 
genetics and cytogenetics 1987, 27(1):125-134.
12. Jass JR, Sobin LH, Watanabe H: The World Health Organization's 
histologic classification of gastrointestinal tumors. A commentary on 
the second edition.  Cancer 1990, 66(10):2162-2167.
13. General rules for clinical and pathological studies on cancer of the 
colon, rectum and anus. Part II. Histopathological classification. 
Japanese Research Society for Cancer of the Colon and Rectum.  Jpn J 
Surg 1983, 13(6):574-598.
14. Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P, Jaramillo E, Rubio C, 
Koizumi K, Hirakawa K, Boland CR: Genetic pathways in the evolution of 
morphologically distinct colorectal neoplasms.  Cancer research 2001, 
61(6):2676-2683.
15. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt 
RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, et al.: A 
National Cancer Institute Workshop on Microsatellite Instability for 
cancer detection and familial predisposition: development of 
international criteria for the determination of microsatellite instability 
in colorectal cancer.  Cancer research 1998, 58(22):5248-5257.
16. Carethers JM, Pham TT: Mutations of transforming growth factor beta 1 
type II receptor, BAX, and insulin-like growth factor II receptor genes in 
microsatellite unstable cell lines.  In Vivo 2000, 14(1):13-20.
17. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR: Review of 
the Lynch syndrome: history, molecular genetics, screening, 
differential diagnosis, and medicolegal ramifications.  Clinical genetics 
2009, 76(1):1-18.
18. Imai K, Yamamoto H: Carcinogenesis and microsatellite instability: the 
interrelationship between genetics and epigenetics.  Carcinogenesis 
2008, 29(4):673-680.
19. Akiyama Y, Yagi OK, Ishikawa T, Nagasaki H, Saitoh K, Yuasa Y: Genetic 
alterations are frequent in APC but rare in the TGF-beta type II receptor 
gene in cancer in adenomas of the colon.  Cancer Lett 1998, 125(1-
2):89-96.
20. Konishi M, Kikuchi-Yanoshita R, Tanaka K, Muraoka M, Onda A, Okumura Y, 
Kishi N, Iwama T, Mori T, Koike M, et al.: Molecular nature of colon tumors 
in hereditary nonpolyposis colon cancer, familial polyposis, and 
sporadic colon cancer.  Gastroenterology 1996, 111(2):307-317.
21. Grady WM, Rajput A, Myeroff L, Liu DF, Kwon K, Willis J, Markowitz S: 
Mutation of the type II transforming growth factor-beta receptor is 
coincident with the transformation of human colon adenomas to 
malignant carcinomas.  Cancer research 1998, 58(14):3101-3104.
22. Shin KH, Park YJ, Park JG: Mutational analysis of the transforming growth 
factor beta receptor type II gene in hereditary nonpolyposis colorectal 
cancer and early-onset colorectal cancer patients.  Clin Cancer Res 2000, 
6(2):536-540.
23. Ogata S, Tamura G, Endoh Y, Sakata K, Ohmura K, Motoyama T: 
Microsatellite alterations and target gene mutations in the early stages 
of multiple gastric cancer.  J Pathol 2001, 194(3):334-340.
24. Pinto M, Oliveira C, Cirnes L, Carlos Machado J, Ramires M, Nogueira A, 
Carneiro F, Seruca R: Promoter methylation of TGFbeta receptor I and 
mutation of TGFbeta receptor II are frequent events in MSI sporadic 
gastric carcinomas.  J Pathol 2003, 200(1):32-38.
25. Munoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, Sozmen EG, 
Madison BB, Pozzi A, Moon RT, et al.: Transforming growth factor beta 
receptor type II inactivation induces the malignant transformation of 
intestinal neoplasms initiated by Apc mutation.  Cancer research 2006, 
66(20):9837-9844.
26. Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, 
Konrad L, Laiho P, Espin E, Armengol M, et al.: Mechanisms of inactivation 
of the receptor tyrosine kinase EPHB2 in colorectal tumors.  Cancer 
research 2005, 65(22):10170-10173.
27. Woerner SM, Benner A, Sutter C, Schiller M, Yuan YP, Keller G, Bork P, 
Doeberitz MK, Gebert JF: Pathogenesis of DNA repair-deficient cancers: 
a statistical meta-analysis of putative Real Common Target genes.  
Oncogene 2003, 22(15):2226-2235.
28. Korff S, Woerner SM, Yuan YP, Bork P, von Knebel Doeberitz M, Gebert J: 
Frameshift mutations in coding repeats of protein tyrosine 
phosphatase genes in colorectal tumors with microsatellite instability.  
BMC cancer 2008, 8:329.
29. Kim JJ, Baek MJ, Kim L, Kim NG, Lee YC, Song SY, Noh SH, Kim H: 
Accumulated frameshift mutations at coding nucleotide repeats 
during the progression of gastric carcinoma with microsatellite 
instability.  Lab Invest 1999, 79(9):1113-1120.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/303/prepub
doi: 10.1186/1471-2407-10-303
Cite this article as: Yashiro et al., Mutations in TGFbeta-RII and BAX mediate 
tumor progression in the later stages of colorectal cancer with microsatellite 
instability BMC Cancer 2010, 10:303
Received: 12 February 2010 Accepted: 18 June 2010 
Published: 18 June 2010
This article is available from: http://www.biomedcentral.com/1471-2407/10/303© 2010 Yashiro et l; licensee BioMed Central Lt . is an Open Access articl d stributed under th  terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC C c r 2010, 10:303
